147027-04-1

Basic information

• Product Name: 1,3-OXATHIOLANE-2-CARBOXYLIC ACID, 5-HYDROXY-, TRANS-
• Synonyms: 1,3-OXATHIOLANE-2-CARBOXYLIC ACID, 5-HYDROXY-, TRANS-;1,3-Oxathiolane-2-carboxylicacid,5-hydroxy-,trans-(9CI);A mixture of: trans-(2R)-5-acetoxy-1,3-oxathiolane-2-carboxylic acid cis-(2R)-5-acetoxy-1,3-oxathiolane-2-carboxylic acid;rac-trans-5-Hydroxy-1,3-oxathiolane-2-carboxylic Acid;LOWHAEXKCMFUMV-OKKQSCSOSA-N
• CAS NO: 147027-04-1
• Molecular Formula: C4H6O4S
• Molecular Weight: 150.15304
• EINECS: 411-660-8
• Product Categories: CARBOXYLICACID;Nucleotides, Bases & Related Reagents
• Mol File: 147027-04-1.mol

Chemical Properties

• Boiling Point: 434.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.697±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 2.13±0.40(Predicted)
• Stability: Epimerize in solution
• CAS DataBase Reference: 1,3-OXATHIOLANE-2-CARBOXYLIC ACID, 5-HYDROXY-, TRANS-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-OXATHIOLANE-2-CARBOXYLIC ACID, 5-HYDROXY-, TRANS-(147027-04-1)
• EPA Substance Registry System: 1,3-OXATHIOLANE-2-CARBOXYLIC ACID, 5-HYDROXY-, TRANS-(147027-04-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-38-41-43
• Safety Statements: 22-24-26-37/39
• Hazardous Substances Data: 147027-04-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1,3-OXATHIOLANE-2-CARBOXYLIC ACID, 5-HYDROXY-, TRANSis used as a key intermediate in the synthesis of potent antiviral agents, specifically (-)-2'-Deoxy-3'-thiacytidine and its enantiomer. These antiviral agents are crucial in the treatment of various viral infections, including HIV and hepatitis.
The compound's unique structure allows it to be easily modified and incorporated into the synthesis of other antiviral drugs, making it a valuable asset in the development of new therapeutics. Its use in the pharmaceutical industry is primarily focused on the creation of novel antiviral agents, which can help combat the growing threat of drug-resistant viruses and improve patient outcomes.

Upstream product

• 40018-26-6 1,4-dithiane-2,5-diol 
• 298-12-4 Glyoxilic acid 
• 6000-59-5 glyoxalic acid monohydrate 

Downstream Products

• 440105-45-3 TRANS-5-ACETOXY-1,3-OXATHIOLANE-2-CARBOXYLIC-ACID 

Relevant articles and documents

COMPOUNDS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES

The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR

The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of a TLR7 agonist and an HBV capsid assembly inhibi

Practical enantioselective synthesis of lamivudine (3TC) via a dynamic kinetic resolution

A practical enantioselective synthesis of lamivudine 1 is described. A highly effective dynamic kinetic resolution of the 5-hydroxyoxathiolane, followed by chlorination and introduction of cytosine provides an efficient synthesis of lamivudine.

Processes for the diastereoselective separation of nucleoside analogue synthetic intermediates

The present invention relates to highly diastereoselective processes for production of cis-nucleosides and nucleoside analogues and derivatives in high optical purity and intermediates useful in those processes.

Processes for the diastereoselective synthesis of nucleoside analogues

The present invention relates to highly diastereoselective processes for production of cis-nucleosides and nucleoside analogues and derivatives in high optical purity, and intermediates useful in those processes.